Improvement of Cutaneous Hereditary Hemorrhagic Telangiectasia With Pazopanib-A Multikinase Inhibitor

JAMA Dermatol. 2022 Feb 1;158(2):214-216. doi: 10.1001/jamadermatol.2021.5132.

Authors

June Young Moon¹, Etsubdenk M Ajebo¹, James R Gossage², Matthew D Belcher¹

Affiliations

¹ Department of Dermatology, Medical College of Georgia at Augusta University, Augusta.
² Division of Pulmonary, Critical Care, and Sleep Medicine, Medical College of Georgia at Augusta University, Augusta.

PMID: 34910078
DOI: 10.1001/jamadermatol.2021.5132

No abstract available

MeSH terms

Humans
Indazoles
Pyrimidines / therapeutic use
Sulfonamides / therapeutic use
Telangiectasia, Hereditary Hemorrhagic* / diagnosis
Telangiectasia, Hereditary Hemorrhagic* / drug therapy

Substances

Indazoles
Pyrimidines
Sulfonamides
pazopanib